{"Content: ":"The first case of the COVID-19 pandemic in the Indian state of Haryana was reported on 4 March 2020.[1] The Ministry of Health and Family Welfare has confirmed a total of 2,64,955 positive cases as of 10 January 2021 out of which 2,510 are still active and 2,950 deaths so far. The recovery rate in Haryana is 97.9%.[2] Data reference:[3][failed verification] Six (8) labs, one each at PGIMS, Rohtak, BPS Khanpur Kalan, Sonipat, ESIC Hospital, Faridabad, Kalpana Chawla Medical College, Karnal, ICAR-National Research Centre on Equines, Hisar, PGIMER Chandigarh, CSIR Mohali, Civil Hospital, Panchkula are already functional for testing of COVID-19. Five private labs at Gurugram (Modern Diagnostics and Research Lab, SRL, CORE Diagnostics, Pathkind Diagnostics Pvt. Ltd., Dr. Lal Pathlabs) approved by ICMR for COVID-19 testing. 6 government/ aided medical colleges namely PGIMS in Rohtak, BPSGMC in Khanpur Kalan (Sonepat), SHKMGMC in Nalhar, Nuh, KCGMC, Karnal, MAMC, Agroha and 27 hospitals will have dedicated exclusive wards/blocks for COVID-19 patients only. ESIC Medical College, Faridabad is under process for COVID-19 hospital. All government/ government aided/ private medical colleges in the state have been asked to reserve at least 25% of the beds. Isolation wards and quarantine facilities are established as given below: 34,876 isolation beds identified in 601 government and private facilities. 21,188 persons quarantine facility identified in 6133 rooms/dormitories. On January 1, 2021, the Drug Controller General of India, approved the emergency or conditional use of AstraZeneca's COVID-19 vaccine AZD1222 (marketed as Covishield).[9] Covishield is developed by the University of Oxford and its spin-out company, Vaccitech.[10] It is a viral vector vaccine based on replication-deficient adenovirus that causes cold in chimpanzees. It can be stored, transported and handled at normal refrigerated conditions (28 degrees Celsius/ 36-46 degrees Fahrenheit). It has a shelf-life of at least six months. On 12 January 2021 first batches of Covishield vaccine was despatched from the Serum Institute of India.[11] On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech in association with the Indian Council of Medical Research and National Institute of Virology received approval from the Drug Controller General of India for its emergency or conditional usage.[12] On 14 January 2021 first batches of Covaxin vaccine was despatched from the Bharat Biotech, albeit it was still in the third phase of testing.[13] On 19 May 2021, Dr Reddy's Labs received Emergency Use Authorisation for anti-COVID drug 2-DG.[14] On 21 February, 2022, Drugs Controller General of India granted approval to Biological E's COVID-19 vaccine Corbevax, that can be used for children between 12-18 years of age.[15][16] On 21 October 2021, India completed administering of one billion Covid vaccines in the country.[17] On 8 January 2022, India crossed 1.5 billion Covid vaccines milestone in the country.[18] On 19 February 2022, India crossed 1.75 billion Covid vaccines milestone in the country.[19]","Title":"COVID-19 pandemic in Haryana - Wikipedia","KeyID":"10404","URL":"https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Haryana"}